Welcome to our dedicated page for Compugen SEC filings (Ticker: CGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Compugen Ltd. files foreign-issuer reports that document its clinical-stage cancer immunotherapy business, financial results and material corporate developments. Its Form 6-K filings cover quarterly and annual results, interim consolidated financial statements, management discussion and analysis, Inline XBRL financial data, and corporate updates related to programs such as COM701, COM902, rilvegostomig and GS-0321.
The filing record also documents licensing and royalty arrangements, including amendments to the AstraZeneca rilvegostomig agreement, as well as proxy materials, annual general meeting voting results, board composition and registration-statement incorporation matters under Form F-3. These disclosures frame Compugen's capital resources, collaboration economics, governance actions, clinical-development disclosures and foreign private issuer reporting obligations.
Compugen Ltd director Sanford S. Zweifach reported his initial holdings, including 12,680 Ordinary Shares, which include 9,216 restricted stock units that vest over time, subject to continued service. He also holds several share options to buy Ordinary Shares at exercise prices between $1.15 and $14.40, with expirations from 2029 through 2035.
COMPUGEN LTD filed an initial ownership report for its Chief Financial Officer, David Silberman. The filing lists his current equity holdings rather than new market transactions.
He directly holds Ordinary Shares and two sets of share options over Ordinary Shares. One option covers 65,000 underlying Ordinary Shares at an exercise price of $1.6900 per share, expiring on July 31, 2034. A second option covers 24,000 underlying Ordinary Shares at an exercise price of $1.4600 per share, expiring on August 5, 2035.
Footnotes explain that these options and related RSUs vest over time starting on September 30, 2026, with the remaining portions vesting in regular quarterly installments, subject to Mr. Silberman’s continued service to the company.
Compugen Ltd director Livnat Savitzky Kinneret filed an initial ownership report showing direct holdings of ordinary shares, restricted stock units (RSUs), and stock options. She holds 13,350 ordinary shares, including 9,216 RSUs. Of these RSUs, 1,716 vest in 11 equal quarterly installments commencing on April 1, 2026, and 7,500 vest 25% on October 1, 2026 with the remainder in 12 equal quarterly installments thereafter, all subject to continued service.
The filing also lists several option awards over ordinary shares with exercise prices ranging from $1.15 to $14.40 per share and expiration dates from August 6, 2028 through August 5, 2035. These options have various vesting schedules, including grants that are fully vested and others that vested or vest 25% on specific dates such as April 1, 2023, October 1, 2024, October 1, 2025, and October 1, 2026, with remaining portions in 12 equal quarterly installments, conditioned on her continued service to Compugen.
Compugen Ltd. director Eran Perry has filed an initial Form 3 reporting his equity holdings in the company. He directly owns 10,000 Ordinary Shares and 9,216 restricted stock units, which vest in scheduled quarterly installments starting on April 1, 2026 and October 1, 2026, subject to continued service. He also holds multiple share options over Ordinary Shares with exercise prices ranging from $1.15 to $14.40 per share and expiration dates between July 1, 2029 and August 5, 2035, with portions already vested and the remainder vesting in equal quarterly installments.
Compugen Ltd’s President and CEO, Ophir Eran, filed an initial statement of ownership showing both ordinary shares and stock options in the company. He directly holds 11,375 ordinary shares, including 7,821 restricted stock units that begin vesting in 11 equal quarterly installments starting on March 31, 2026, subject to continued service. He also holds multiple share options over Compugen ordinary shares with exercise prices ranging from $0.8292 to $14.4000, expiring between 2026 and 2035, many of which vest or continue vesting in quarterly installments tied to ongoing service.
Compugen Ltd Chief Medical Officer Michelle Mahler filed an initial ownership report showing option and share holdings in the company. She holds share options over 40,000, 35,750 and 18,000 Ordinary Shares with exercise prices of $0.8793, $1.6900 and $1.4600, expiring between 2033 and 2035. She also holds 23,125 Ordinary Shares, including 20,122 restricted stock units that vest gradually in quarterly installments starting on March 31, 2026 and September 30, 2026, conditioned on continued service.
Compugen Ltd filed an initial Form 3 for Zurit Levine, SVP, Business Development, detailing existing equity holdings. Levine directly holds 29,375 Ordinary Shares, including 25,821 restricted stock units that vest in staged quarterly installments. She also holds multiple share options over Ordinary Shares with exercise prices between 0.8292 and 14.4000, expiring from 2026 through 2035. These entries reflect current positions, not new market purchases or sales.
COMPUGEN LTD director Mathias Hukkelhoven filed an initial ownership report showing his existing equity stake in the company. The filing lists direct holdings of 10,000 Ordinary Shares and several stock option awards over Ordinary Shares with different exercise prices and maturities.
He holds options over 35,000 Ordinary Shares at an exercise price of $3.09 expiring in 2032, 10,000 shares at $1.15 expiring in 2033, 8,000 shares at $1.69 expiring in 2034, 12,000 shares at $1.97 expiring in 2034, and 10,000 shares at $1.46 expiring in 2035.
The disclosure also notes 9,216 restricted stock units, with portions vesting in quarterly installments starting on April 1, 2026 and on October 1, 2026, subject to his continued service. The document records holdings only and does not show new purchases or sales.
Compugen Ltd director Michele Holcomb filed an initial ownership report showing equity awards tied to her service. She holds 15,000 Ordinary Shares directly and a share option for 20,000 Ordinary Shares at an exercise price of $1.76 per share, expiring on February 11, 2036. The option vests 25% on April 1, 2027, with the remainder vesting in 12 equal quarterly installments, and related RSUs follow the same vesting schedule, all subject to her continued service to Compugen.
Compugen Ltd director Halevy Gilead has filed an initial ownership report detailing existing equity awards and shareholdings. The filing lists several share options over Ordinary Shares with exercise prices ranging from $1.15 to $14.40 per share and expirations between 2028 and 2035. It also shows direct ownership of 11,407 Ordinary Shares. Footnotes state that this share figure includes 9,216 restricted stock units, with portions scheduled to vest in quarterly installments beginning on April 1, 2026 and on October 1, 2026, subject to continued service.